HSCT in children with sickle cell Disease

Slides:



Advertisements
Similar presentations
Cord Blood Transplantation: Umbilical Blood As Hematopoietic Stem Cell Source Analysis of theoretical/clinical advantages/disadvantages Comparison with.
Advertisements

Hematopoietic Stem Cell Transplantation Lynn Savoie September 30, 2006.
Congenital Neutropenia: Making the Decision to Transplant John E. Levine, MD, MS University of Michigan Blood and Marrow Transplantation Program.
By: Alejandra Arellano
Empowering hospital patients as partners in their diagnosis and treatment The example of bone marrow transplantation Hildegard Greinix Medical University.
Bone Marrow Transplant in Oncology
Questions and Answers about Bone Marrow Stem Cell Transplantation prepared by the Armenian Bone Marrow Donor Registry.
Hematopoietic Stem Cells A hematopoietic stem cell is a cell isolated from the blood or bone marrow that can renew itself, can differentiate to a variety.
Blood and marrow stem cell transplantation A.Basi ADULT HEMATOLOGIST,ONCOLOGIST IRAN UNIVERSITY OF MEDICAL SCIENCES.
Hematopoietic Stem Cell Transplantation (HSCT) Overview Willis H Navarro, MD Medical Director, Transplant Services, NMDP Associate Clinical Professor,
Bone Marrow Transplantation. Unlike solid organ transplant, in bone marrow transplantation (BMT) the immunology goes two ways. There is host vs. ​ graft.
ETHICS for LUNCH: Parental Request for Experimental Therapy for a Child J.M. Lorenz, MD February 16, 2006.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2010 CIBMTR Summary Slides SUM10_1.ppt.
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2011 Summary Slides Worldwide SUM-WW11_1.ppt.
Hematopoietic Stem Cell Transplant
Building Canada’s National Public Cord Blood Bank.
ELTR 12/2008 The Present Evolution of Liver Transplantation 1. General evolution of LT in Europe 2. Donor data 3. Recipient data 4. Indications and results.
Asma Sultan Alolama, MD Private Cord Blood Banking Should it be allowed? Asma Sultan Alolama, M.D.
Kelsey Cramer. MEET MY AUNT DONATING BONE MARROW.
SICKLE CELL ANEMIA Prepared by: Tuba Kartal Özge Özütrk.
What about stem cell transplantation? Dr Catherine Flynn Consultant Haematologist St James’s Hospital 17/06/2011.
Sickle Cell Anemia. P. falciparum – Blood stages Uninfected RBC 2 hr. 4 hr. 12 hr.
RESULTS FROM THE 2007 SHOT REPORT. SHOT report 2007 (561 cases)
Haemoglobinopathies.
RESULTS FROM THE 2006 SHOT REPORT. SHOT report 2006.
Harvey Luksenburg, Ph.D. National Heart, Lung, & Blood Institute two years of the initial event. The NIH’s Role in the Prevention and Reduction of Strokes.
Kidney Disorders. Kidney Transplant Many consider this to be the best method of treating kidney disease. A transplant may offer the best chance.
Immunology of transplantation. Types of transplantation Autotransplantation –within one organism Allotransplantation- between one species Xenotransplantation-
Successful sequential cord blood stem cell transplant and intestinal-colon transplant for combined immunodeficiency and intestinal failure.
Bone marrow Transplant in Paediatric Haematology
Sickle Cell Disease By Samantha.
Sickle Cell Disease Taeron Burrell. What Is Sickle Cell Anemia? Sickle cell Anemia is a serious disorder in which the body makes sickle shape blood cells.
HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.
Platelet Transfusions Indications, dose and administration
Bone Marrow Donation. What is Bone marrow?  flexible spongy tissue in the interior of bones such as your hip and thigh.  constitutes 4% of the total.
HAPLOIDENTICAL STEM CELL TRANSPLANT
HAEMATOPOIETIC STEM ELL TRANSPLANTATION (HSCT) A process in which abnormal, malignant, or non- functioning marrow cells are replaced with normal marrow.
New Approaches for Transplant Patients Linda J Burns, MD Medical Director, Health Services Research Program National Marrow Donor Program (NMDP)/Be the.
Dr. Kasi Viswanathan, Head Dept. Of Haematology & Bone marrow transplantation Dept. Of Pediatric Oncology, Meenakshi Mission Hospital & Research Centre,
Issues in Organ Donation. Organ Transplants  More than 200,000 people in the U.S. suffer from kidney failure.  Treatment of kidney failure generates.
Bone Marrow Transplant
(Donor T-Cells Transduced with iC9 Suicide Gene)
Renal vascular disease
Blood and Marrow Transplant: The basics…what you need to know
Stem Cell Transplantation
Other Whitesides Research
3.1 Review PBS.
Whose Blood Is It, Anyway?
Treatment of Aplastic Anemia
RIC UCBT Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning.
Supplemental table 1 Patients' characteristics Variables Number
Man & Environment: Biomedical Development
3.1 Review PBS.
Human Health and Disease
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
Childhood Cancer Polly Bennion.
Stem Cells and Cellular Differentiation
Assessment of Allogeneic HCT in Older Patients with AML and MDS: A CIBMTR Analysis McClune B et al. ASCO/ASH Symposium 2009;The Best of ASH Special & Plenary.
Interesting Case Conference
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION for MULTIPLE MYELOMA
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia  Robert Iannone, James F Casella, Ephraim.
Timing for HCT Consultation
Letermovir(Prevymis™) Guidelines for Inpatient Use
Bone Marrow Transplantation Using HLA-Matched Unrelated Donors for Patients Suffering from Severe Combined Immunodeficiency  Eyal Grunebaum, MD, Chaim.
Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.
Hematopoietic Cell Transplantation for Children with Acute Lymphoblastic Leukemia in Second Complete Remission: Similar Outcomes in Recipients of Unrelated.
Introduction. Title: Activities and Outcomes of Hematopoietic Cell Transplantation in Japan.
Sickle cell disease By Mayu & Jovany.
To Be or Not To Be: Ethical Issues in Curative Therapies for Sickle Cell Disease Lakshmanan Krishnamurti, MD Kathleen Spencer, RN, MSN, CPNP.
How I treat acquired aplastic anemia
Presentation transcript:

HSCT in children with sickle cell Disease

the Majority in children with an HLA matchel sibling donor HSCT is currently the only curative option for SCD) To Date , about 1200 Transplants has been reported in the European and us transplant registries the Majority in children with an HLA matchel sibling donor Using MSD and myebablative regime ,the rate for mortality ,rejection and cure are 5% , 5% and 90% Respectively After HSCT VOCs are abolished , CNS diesase stabilized (but )usually not improved . TCD normalized and QOL is much improved

Long Term complication of HSCT in children include loss of fertility due to primary gonadal failure / skeletal complication (osteoporosis) Very Small increase in the risk of malignant disease Long term outcome is generally much in favour of BMT compared to standard care

Current indication for matched sibling HSCT in children Recurrent VOC complication (acute pain or ACS) not responding to Hydroxyurea Past History of ischemic stroke or sever cerebral vasculopathy Abnormal TCD flow with evidence of ischemic cerebral damage Sever avascular necrosis Multiple red cell alloantibody restricting availability of blood for transfusion

Nephropathy Problem relating to future care(e.g likely return to home country where health care services are inadequate) Any child with Hb ss irrespective of severity , if an HLA compatible sibling donor is available.

Risk and Benefits Most specialist begin the dicussion about possible HSCT with parents early during the first year Of life And then at the appropriate occasion later childhood

The first outcome of this discussion is an agreement for compatibility testing of sibling (if available) If a donor is identified a fuller Discussion and assessment is initiated , together With referral to a specialist transplant unit.

The decision to go ahead can be very difficult for parents because it is difficult to predict long-term prognosis for young child who may not be particularly severely affected at the time of the discussion

The transplant procedure HSCT in SCD should only be performed in centers experienced in transplanting hemoglobinopathy patients Acute GVHD appears to be increased with use of donor peripheral blood and bone marrow is advised as a source of donor stem cells

There is a higher risk of delayed engraftment with umbilical cord Blood transplants. Cord blood is generally not recommended as the sole source of stem cell ,at least in older children.

There are specific requirements for conditioning in SCD transplants including pre- transplant hypertransfusion and marrow suppression with hydorxyurea Granulocyte colony stimulating Factor (GCSF)is not used for stimulation of neutrophile Recovery because of the risk of precpitating a severe VOC crisis.

In addition to higher risk of acute neurological events in the presence of cerebral vasculopathy there is also a significant increased risk of PRES

Alternative Donor 10-15% of patients have an HLA mathed sibling Donor Alternative include MUD/or haplo identical (half matched) familiy donors In general mortality and morbidity are increased with the use of alternative donors Considered in patients with sever complication of SCD

They should only be undertaken as part of a research practice . The graft failure rate is over 50% which is unacceptable

HSCT in adults The outcomes for adult using HLA.matched sibling donors are poorer than In children A recent single – center study using non-myeloablative conditioning and a novel immunosuppressive regime has reported long term stable mixed donor- recipient chimerism (donor and host cells co-existing )in 9 of 10 patients

Indication for transplant included irreversible and end-organ damage stroke or other significant CNS events Interestingly some of patient had severe acute and chronic pain which gradually resolved enabling withdrawal of chronic opioid medication Unfortunately the requirement for an HLA matched sibling donor still restricts this approach to a small minority of adult patients.

Umbilical cord blood HSCT and storage of cord blood UCB from babies who are HLA matched can be stored and used as a source of HSC This scenario would usually occur after PND has confirmed that the sibling is unaffected and subsequent HLA typing of the CVS sample has confirmed HLA matching . Storage without PND cord blood banking would probably not be funded by health authorities.